SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-----------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
August 14, 2008
---------------
Date of Report
(Date of earliest event reported)
MIDDLEBROOK PHARMACEUTICALS, INC.
---------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50414 52-2208264
-------- --------- ----------
(State or Other (Commission File Number) (IRS Employer Identification No.)
Jurisdiction of
Incorporation)
20425 Seneca Meadows Parkway, Germantown, Maryland 20876
--------------------------------------------------------
(Address of Principal Executive (ZIP Code)
Offices)
Registrant's telephone number, including area code: (301) 944-6600
--------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 14, 2008, MiddleBrook Pharmaceuticals, Inc. issued a press
release announcing its financial results for the three months and six months
ended June 30, 2008. A copy of the release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
The information in this Form 8-K and the Exhibit attached hereto shall
not be deemed "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Description
------- -----------
99.1 Press Release issued August 14, 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MIDDLEBROOK PHARMACEUTICALS, INC.
Date: August 14, 2008 By: /s/ Robert C. Low
----------------------------------
Robert C. Low
Vice President, Finance and
Chief Financial Officer